A Study of LY3006072 in Healthy Participants

Phase 1

Terminated

Brief Summary: The purpose of this study is to evaluate how safe LY3006072 (study drug) is and whether it causes any side effects. The study will also measure how much of the study drug gets into the blood stream and how long it takes the body to get rid of the study drug. The study drug will be given in the morning or evening with or without a meal.

This is the first time that this study drug is being given to humans. This study is for research purposes only and is not intended to treat any medical condition.

Detailed Description: This study has two parts:

Part A - single ascending dose of LY3006072 administered to healthy participants in 3 of 4 study periods (placebo in 1 of 4 periods).

Part B - morning and evening doses of LY3006072 given to healthy participants in fed and fasted states in 2 or 3 of 3 study periods (placebo in 1 of 3 periods for some participants).

Recruitment & Eligibility

Inclusion Criteria

Overtly healthy males or females, as determined by medical history and physical examination
Male participants with a partner of childbearing potential must agree to use barrier protection during sexual intercourse while in the study and for 3 months after the last dose of study drug
Women must not be pregnant or nursing and must be of non-childbearing potential, due to either surgical sterilization or menopause
Body mass index between 19.0 and 30.0 kilograms per square meter (kg/m^2), inclusive

Exclusion Criteria

Not provided

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Participants received placebo capsule orally with approximately 200 to 300 milliliter (mL) of room temperature water in the morning.
LY3006072	LY3006072	Participants received LY3006072 capsules starting at 1 milligram (mg) and escalating doses of 3 mg, 10 mg, 20 mg and 40 mg.

Primary Outcome Measures

Name	Time	Method
Number of Participants With One or More Drug Related Adverse Events (AEs) or Any Serious AEs	Baseline, up to 21 days	AEs that were considered possibly related to study drug, in the opinion of the investigator, were reported. A summary of serious and all other non-serious AEs, regardless of possible drug relatedness, is located in the Reported Adverse Event module.

Secondary Outcome Measures

Name	Time	Method
Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY3006072	Predose, 0.25, 0.5, 1, 2, 3, 5, 8, 12, 16, 24, 36, 48 and 96 hours postdose	PK: Area Under the Concentration-Time Curve from Time Zero to Infinity (AUC\[0-inf\] of LY3006072.
Pharmacokinetics: Maximum Concentration (Cmax) of LY3006072	Predose, 0.25, 0.5, 1, 2, 3, 5, 8, 12, 16, 24, 36, 48 and 96 hours postdose

Locations (1): For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
🇺🇸
Evansville, Indiana, United States